New EU regulatory initiatives will introduce changes for financial markets in Europe.
MiFID II, PRIIPs and the Benchmark Regulation (BMR) are introducing new obligations for EU trading venues and their participants.
CME Group’s markets are established in the U.S. under the CFTC’s regulatory framework. In some cases, these EU regulatory initiatives may extend to certain transactions executed on CME Group’s markets and where possible we will assist these firms with the compliance of their obligations.
Certain provisions in relation to the EU Regulation on Benchmarks (BMR) came into effect 1 January 2018. Administrators of benchmarks provided to EU supervised entities, and use of benchmarks by those entities (as described by the BMR) became subject to new EU regulatory requirements.
On 8 November 2017, ESMA provided guidance that the transitional provisions applicable to third country benchmarks under Article 51(5) apply where the benchmark is used in the Union on or before 1 January 2020.
Therefore all prices and data provided by CME Group are available for use by EU supervised entities throughout the transitional period until 1 January 2020, subject to having entered into appropriate licensing arrangements where relevant. We will update market participants regarding our approach under the BMR closer to the expiry of the transitional period.
CME Group is happy to assist and to provide information in relation to participation in our U.S. markets, however please note we cannot provide legal advice, so any information we share is purely based on our interpretation and does not constitute legal or other advice. You should always undertake your own research or obtain your own advice relating to your legal or regulatory obligations, and should not rely on any information provided by CME Group.